We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-14.47%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$399M
AUM Growth
–
Cap. Flow
+$416M
Cap. Flow %
104.44%
Top 10 Hldgs %
83.96%
Holding
24
New
24
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$91.1M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$80.1M
3
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$28.4M
4
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$27.1M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$26.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 65.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$739M
$79.4M 19.92%
+4,191,397
New +$80.1M
SGNT
2
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$79.1M 19.84%
+6,499,737
New +$91.1M
BITI
3
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$32.5M 8.16%
+1,220,234
New +$28.4M
NBRV
4
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$28.2M 7.08%
+12,607
New +$27.1M
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$26.8M 6.73%
+53,320
New +$26.5M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.3B
$26.3M 6.6%
+1,419,332
New +$25.2M
CDXS icon
7
Codexis
CDXS
$136M
$17.3M 4.35%
+5,573,319
New +$21.5M
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$16.4M 4.12%
+60,957
New +$19.5M
AAAP
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$16M 4%
+455,798
New +$13.7M
AGRX
10
DELISTED
Agile Therapeutics
AGRX
$12.5M 3.15%
+1,010
New +$13M
RGNX icon
11
Regenxbio
RGNX
$606M
$10.7M 2.68%
+990,449
New +$12.7M
TRVN
12
DELISTED
Trevena, Inc.
TRVN
$9.92M 2.49%
+1,920
New +$9.67M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$8.88M 2.23%
+99,551
New +$9.75M
KITE
14
DELISTED
Kite Pharma, Inc.
KITE
$8.87M 2.22%
+193,193
New +$9.36M
AKTX
15
Akari Therapeutics
AKTX
$14.4M
$7.39M 1.85%
+660
New +$6.84M
DVAX
16
DELISTED
Dynavax Technologies
DVAX
$6.88M 1.73%
+357,755
New +$7.23M
LITS
17
Lite Strategy Inc
LITS
$33.4M
$3.49M 0.87%
+138,386
New +$3.45M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$2.69M 0.68%
+300,326
New +$5.38M
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
$2.21M 0.55%
+887,906
New +$3.23M
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.89M 0.47%
+77,373
New +$1.57M
OCRX
21
DELISTED
Ocera Therapeutics, Inc.
OCRX
$451K 0.11%
+153,331
New +$437K
ZSAN
22
DELISTED
Zosano Pharma Corporation
ZSAN
$227K 0.06%
+141
New +$232K
CAPNW
23
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$215K 0.05%
+932,910
New +$279K
PTN
24
Palatin Technologies
PTN
$13.4M
$127K 0.03%
+188
New +$122K

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q1 2016 Portfolio in Review

Q1 2016 is the first quarter with a 13F filing on record for Vivo Capital, which disclosed 24 positions worth $399M. Its ten largest holdings account for 84% of the portfolio.

Its largest position is SAGENT PHARMACEUTICALS INC COM STK (DE): 6,499,737 shares worth $79.1M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets.

  • Vivo Capital's largest Q1 2016 buy was SAGENT PHARMACEUTICALS INC COM STK (DE): 6,499,737 shares worth $79.1M.
  • Vivo Capital's ten largest holdings make up 84% of its $399M portfolio in Q1 2016.
  • Vivo Capital disclosed 24 positions in Q1 2016, its first 13F filing on record.

Based on Vivo Capital's 13F filing for Q1 2016, filed 16 May 2016.